DARE vs. ENLV, CASI, JAN, THTX, DRRX, FBIO, VIRX, SPRB, IPA, and NXTC
Should you be buying Daré Bioscience stock or one of its competitors? The main competitors of Daré Bioscience include Enlivex Therapeutics (ENLV), CASI Pharmaceuticals (CASI), JanOne (JAN), Theratechnologies (THTX), DURECT (DRRX), Fortress Biotech (FBIO), Viracta Therapeutics (VIRX), Spruce Biosciences (SPRB), ImmunoPrecise Antibodies (IPA), and NextCure (NXTC). These companies are all part of the "pharmaceutical preparations" industry.
Daré Bioscience (NASDAQ:DARE) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends, community ranking and analyst recommendations.
Daré Bioscience received 303 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Enlivex Therapeutics an outperform vote while only 73.18% of users gave Daré Bioscience an outperform vote.
6.7% of Daré Bioscience shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 5.3% of Daré Bioscience shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Enlivex Therapeutics' return on equity of -71.00% beat Daré Bioscience's return on equity.
Daré Bioscience presently has a consensus target price of $6.00, indicating a potential upside of 1,828.02%. Enlivex Therapeutics has a consensus target price of $7.00, indicating a potential upside of 332.10%. Given Daré Bioscience's higher probable upside, equities research analysts clearly believe Daré Bioscience is more favorable than Enlivex Therapeutics.
In the previous week, Daré Bioscience had 8 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 9 mentions for Daré Bioscience and 1 mentions for Enlivex Therapeutics. Enlivex Therapeutics' average media sentiment score of 0.84 beat Daré Bioscience's score of 0.10 indicating that Enlivex Therapeutics is being referred to more favorably in the news media.
Daré Bioscience has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
Enlivex Therapeutics has lower revenue, but higher earnings than Daré Bioscience. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Daré Bioscience, indicating that it is currently the more affordable of the two stocks.
Summary
Daré Bioscience beats Enlivex Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Daré Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Daré Bioscience Competitors List
Related Companies and Tools
